PATENT CLAIM ANALYSIS

Application Number: 16054899
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "210210"]

Abstract:
A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4  and R 5  are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.

Claim (Index 25):
A method of treating small cell lung cancer associated with a PTEN deficiency in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound:\n (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 1.64615
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13020619', '13972166', '13787496', '13077785', '12510096']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8045679459230656
- 35 USC 102 Novelty (BERT): 0.5587410791273425
- Combined Prediction Score: 0.7799852592434933
- Mean Citation Score: 355.604602
- Max Citation Score: 457.08914
- Similarity Product: 372.38698395547385

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test